Summary Tricida Inc (Tricida), formerly Trilypsa Inc is a clinical-stage pharmaceutical and drug discovery company.The company discovers and develops novel non-absorbed therapies for the treatment of renal, metabolic and cardiovascular diseases.
Its lead drug candidate TRC101, is under clinical development to treat metabolic acidosis a common complication of chronic kidney disease (CKD).Tricida plans to initiate a Phase III study to evaluate the safety and efficacy of TRC101 as a potential treatment for chronic metabolic acidosis associated with CKD.
The company’s portfolio of investors includes OrbiMed, Sibling Capital, Limulus Venture Partners, Longitude Capital and Vivo Capital. Tricida is headquartered in South San Francisco, California, the US.
Tricida Inc (TCDA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings.The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.
The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope - Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company’s operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements - The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy - The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
Orexin Receptor Type 1 - Drugs In Development, 2021 Summary Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Orexin receptor type 1 (Ox1R or OX1) is a protein that is encoded by the HCRTR1 gene. The orexin 1 receptor (OX1) is a G-protein coupled receptor that is highly expressed in...
The Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2021 report provides a detailed understanding and analysis of how and why companies enter clinical stage partnering deals and provides details of the latest clinical agreements announced in the healthcare sector. Understanding the flexibility...
In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global Zero Liquid Discharge (ZLD) Systems Market Report
The zero liquid discharge (ZLD) systems market is expected to reach USD 10.22 billion by 2026, growing at a CAGR of 8.57% during the forecast period 2021-2026
The following factors...
Europe Squalene Market Size, Share & Trends Analysis Report By Source (Animal, Plant, Synthetic), By End Use (Pharmaceuticals, Personal Care & Cosmetics, Nutraceuticals, Food & Beverages), By Country, And Segment Forecasts, 2021 - 2030
Europe Squalene Market Growth & Trends
The Europe squalene...
Real-world data and real-world evidence are used to monitor the post-market safety and adverse events of drugs.The monitoring of this data assists in making regulatory decisions. The healthcare community is using RWE and RWD to support coverage decisions and to develop guidelines and decision support tools for use in clinical practice. The...
The global Micropump market is expected to reach US$ 5,172.86 million in 2028 from as estimated value of US$ 1,553.01 million in 2021. The market is likely to grow with a CAGR of 18.8% from 2021-2028. The growth of the market is due to increasing demand for micropumps in medical device industry, and improved accuracy compared to traditional...
318 pages •
By Future Market Insight Global & Consulting Pvt Ltd
• Jul 2021
Recently a market study published on the defoamers market includes the global and Indian industry analysis for 2016-2020 and opportunity assessment for 2021-2031, and also delivers a comprehensive assessment of the most important market dynamics. Our analysts conduct thorough research on the historical as well as current growth parameters...
The global particle size analysis market reached a value of US$ 351.7 Million in 2020. Looking forward, the analyst expects the market to exhibit moderate growth during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different...
206 pages •
By Asia Market Information & Development Company
• Jun 2021
China’s demand for Dimethylacetamide has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption...
The global empty capsules market is projected to reach USD 3.7 billion by 2026 from USD 2.6 billion in 2021, at a CAGR of 7.2% during the forecast period. The overall growth of the empty capsules market is largely driven by the growing adoption of capsule formulations among the growing geriatric population, the growth of the pharmaceutical...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.